Methiodal

Summary

Methiodal (CHEMBL2110978) is an approved small molecule (ATC V08AA09).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AA09
• Chemistry: 222 Da · CH3IO3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110978
Name	Methiodal
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	31346
ATC	V08AA09
Molecular formula	CH3IO3S
Molecular weight	222
InChIKey	RDFJFVXMRYVOAC-UHFFFAOYSA-N

SMILES: C(S(=O)(=O)O)I

IUPAC name: iodomethanesulfonic acid

Also known as: Methanesulfonic acid, iodo-, Methiodal, METHIODAL

Parent form; salt/anhydrous children: CHEMBL2106907

Patent coverage: 45 distinct patent families (115 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).